CONFERENCE UPDATE: ASH 2021

Pivotal results of phase 1/2 study: Novel mosunetuzumab elicits clinically durable response and deep remission in rrFL patients who underwent ≥2 prior lines of therapy

HEMATOLOGY
28 Jan 2022

Get access to our exclusive articles.
Related Articles

Mosunetuzumab demonstrates consistent efficacy in patients with R/R follicular lymphoma after ≥2 prior treatments: 3-year follow-up from a pivotal phase 2 study

STUDY DESIGN Mosunetuzumab is a T-cell-engaging bispecific antibody that redirects T cells to eliminate malignant B cells.1 It has been approved for the treatment of relapsed and/or refractory (R/R) follicular lymphoma (FL) after ≥2 prior systemic treatments.1 Previous analysis of the pivotal phase
HEMATOLOGY
23 Jan 2024

R2 regimen continues to show survival benefits in patients with RR iNHL: Long-term follow-up from the augment study

HEMATOLOGY
02 Mar 2023

Novel oral EZH2 inhibitor demonstrated to be effective in epithelioid sarcoma and follicular lymphoma

The Lancet Oncology has recently published the phase 2 study results of a novel EZH2 inhibitor. In patients with advanced or metastatic epithelioid sarcoma (ES) and relapsed or refractory follicular lymphoma (FL) that was previously treated, tazemetostat was shown to be well-tolerated with clinicall
ONCOLOGY
30 Dec 2020